GMP-based CD133(+) cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy

The aim of the present study was to develop and validate a good manufacturing practice (GMP) compliant procedure for the preparation of bone marrow (BM) derived CD133(+) cells for cardiovascular repair. Starting from available laboratory protocols to purify CD133(+) cells from human cord blood, we i...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaipa, Giuseppe, Tilenni, Manuela, Straino, Stefania, Burba, Ilaria, Zaccagnini, Germana, Belotti, Daniela, Biagi, Ettore, Valentini, Marco, Perseghin, Paolo, Parma, Matteo, Campli, Cristiana Di, Biondi, Andrea, Capogrossi, Maurizio C, Pompilio, Giulio, Pesce, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2010
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829025/
https://www.ncbi.nlm.nih.gov/pubmed/19627397
http://dx.doi.org/10.1111/j.1582-4934.2009.00854.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829025/
https://www.ncbi.nlm.nih.gov/pubmed/19627397
http://dx.doi.org/10.1111/j.1582-4934.2009.00854.x

Ejemplares similares